
Guidance for Industry

Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact (CDER) Shiew-Mei Huang, 301-796-1541, or Lei Zhang, 301-796-1635.

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**February 2012
Clinical Pharmacology**

Ranbaxy Ex. 1030

Guidance for Industry

Drug Interaction Studies — Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations

Additional copies are available from:

*Office of Communications
Division of Drug Information, WO51, Room 2201
Center for Drug Evaluation and Research
Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002
Phone: 301-796-3400; Fax: 301-847-8714
druginfo@fda.hhs.gov*

<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>

**U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research (CDER)**

**February 2012
Clinical Pharmacology**

TABLE OF CONTENTS

LIST OF FIGURES	2
LIST OF TABLES	2
I. INTRODUCTION.....	1
II. SUMMARY OF GUIDANCE.....	2
III. BACKGROUND	6
A. Relevance of Drug Interactions	6
B. Drug Interaction Considerations for Small Molecule Drugs	7
C. Drug Interaction Considerations for Therapeutic Proteins	14
IV. GENERAL STRATEGIES	14
A. In Vitro Studies	15
B. In Vivo Studies	33
1. <i>In Vivo Drug-Drug Interactions</i>	33
2. <i>In Vivo Drug-Therapeutic Protein (TP) Interactions</i>	33
C. Using a Population Pharmacokinetic Approach to Assess Drug-Drug Interactions ..	36
V. DESIGN OF IN VIVO DRUG-DRUG INTERACTION STUDIES	36
A. Study Design.....	36
B. Study Population.....	39
C. Choice of Substrate and Interacting Drugs	39
D. Route of Administration	55
E. Dose Selection	55
F. Endpoints	56
G. Statistical Considerations and Sample Size	57
VI. LABELING RECOMMENDATIONS.....	58
A. Drug Interactions Section of Labeling.....	59
B. Clinical Pharmacology Section of Labeling	60
C. Other Labeling Sections.....	62
LIST OF FIGURES IN THE APPENDIX.....	63
APPENDIX.....	64
REFERENCES.....	71
ABBREVIATIONS.....	75

List of Figures

Figure 1. Illustration of Examples of Efflux and Uptake Transporters in the Gut Wall (A), Liver (B), and Kidneys (C) that May Be Involved in a Drug’s Absorption, Distribution, Metabolism, and Excretion.	9
Figure 2. Metabolism-Based Drug-Drug Interaction Studies — Decision Tree	16
Figure 3. Evaluation of Investigational Drugs as UGT Substrates.....	20
Figure 4. General Scheme of Model-Based Prediction: The Investigational Drug (and Metabolite Present at $\geq 25\%$ of Parent AUC) as an Interacting Drug of CYP Enzymes	23
Figure 5. Using a PBPK Model to Explore Drug-Drug Interaction Potential Between a Substrate Drug and an Interacting Drug.	29
Figure 6. Evaluation of Investigational Drugs as Substrates for P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, and OCT2 Transporters.	31
Figure 7. Summary of The Types of Studies That Have Been Used During Drug Development to Evaluate Therapeutic Protein (TP)–Small-Molecule Drug (D) Interactions.....	35
Figure 8. The Effect of Various CYP Inhibitors on a Hypertetical Drug’s PK as Displayed as 90% Confidence Interval of Geometric Mean AUC and C_{max} Ratios.....	61

List of Tables

Table 1. Selected Transporter-Mediated Clinical Significant Drug-Drug Interactions.....	12
Table 2. In Vitro CYP Inducers	27
Table 3. Classification of In Vivo Inhibitors of CYP Enzymes	41
Table 4. Classification of In Vivo Inducers of CYP Enzymes	43
Table 5. Examples of Sensitive In Vivo CYP Substrates and CYP Substrates with Narrow Therapeutic Range	44
Table 6. Examples of In Vivo Inhibitors and Inducers of Selected Transporters.....	49
Table 7. Examples of In Vivo Substrates of Selected Transporters	51
Table 8. Examples of In Vivo CYP3A and P-gp Inhibitors and Their Relative Potency.....	53

Guidance for Industry¹

**Drug Interaction Studies — Study Design, Data Analysis,
Implications for Dosing, and Labeling Recommendations**

This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.

I. INTRODUCTION

This guidance provides recommendations for sponsors of new drug applications (NDAs) and biologics license applications (BLAs) for therapeutic biologics regulated by CDER regarding *in vitro* and *in vivo* studies of drug metabolism, drug transport, and drug-drug or drug-therapeutic protein interactions. Drug interactions can result when one drug alters the pharmacokinetics of another drug or its metabolites. Drug interactions also can reflect the additive nature of the pharmacodynamic effect of either drug when taken with the other drug. The main focus of this guidance is pharmacokinetic drug interactions. This guidance reflects the Agency's view that the pharmacokinetic interactions between an investigational new drug and other drugs should be defined during drug development, as part of an adequate assessment of the drug's safety and effectiveness. It is important to understand the nature and magnitude of drug-drug interactions (DDI) for several reasons. Concomitant medications, dietary supplements, and some foods, such as grapefruit juice, may alter metabolism and/or drug transport abruptly in individuals who previously had been receiving and tolerating a particular dose of a drug. Such an abrupt alteration in metabolism or transport can change the known safety and efficacy of a drug.

FDA's guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

¹ This guidance has been prepared by the Drug-Drug Interaction Working Group in the Office of Clinical Pharmacology, Office of Translational Sciences, in the Center for Drug Evaluation and Research (CDER), with input from other offices in CDER.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.